Verily partners with OneOncology: Next-gen SignalPath platform to revolutionize clinical trials in oncology

In a groundbreaking collaboration that promises to reshape the landscape of oncology clinical trials, Alphabet’s precision health tech subsidiary, Verily, is teaming up with OneOncology, the national nexus for independent oncology practices. Central to this strategic partnership is the integration of Verily’s advanced clinical trial management software, SignalPath, into the OneOncology Research Network, known as OneR.

SignalPath’s standout feature, its next-gen protocol digitization technology, seeks to revolutionize the mechanics of clinical trial management. By automating and systematizing study protocol workflows within its platform, SignalPath reduces administrative burden, streamlining processes, bolstering sponsor collaboration, and dramatically improving efficiencies in the research ecosystem.

Dr. Davey Daniel, Chief Medical Officer at OneOncology, emphasized the transformative potential of this partnership, stating, “Harnessing technology to underpin OneR’s platform not only amplifies our partners’ clinical trial capabilities but also democratizes clinical trials, ushering in a new era of health equity.” Indeed, SignalPath’s design directly tackles the cost, time, and complexity associated with conducting clinical trials, prioritizing quality interactions with patients.

Echoing this sentiment, Dr. Brad Hirsch, Head of Product & Implementation at Verily and the co-architect of SignalPath, expressed, “Both Verily and OneOncology share an unwavering commitment to leveraging cutting-edge data and technology to enhance oncology research. SignalPath is a testament to this dedication, simplifying workflows for oncologists, enabling them to concentrate on patient care.”

Beyond improving current practices, this alliance aims for broader horizons. By augmenting research capabilities in community oncology centers, the partnership aspires to boost participation in clinical trials for pioneering cancer treatments. Given the current scenario where over 1,300 anticancer drugs await testing but a mere 6% of US adult cancer patients partake in trials, this is a significant leap forward.

As Verily continually innovates in its research and care product spectrum, OneOncology stands poised to amplify this synergy, with plans for an oncology-centric longitudinal registry to further propel cancer research advancements.